Xadago (Safinamide / Onstryv) Tablets

Comprehensive Guide to Xadago (Safinamide) for Parkinson’s “Off” Episodes

Xadago tablets contain safinamide, a selective monoamine oxidase B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience motor fluctuations, commonly referred to as “off” episodes. In certain countries, safinamide is marketed under the brand name Onstryv; both names refer to the same active ingredient and therapeutic effect.

Parkinson’s disease is a progressive neurodegenerative condition characterised by bradykinesia (slowness of movement), rigidity, tremor, and postural instability. Over time, many patients treated with levodopa develop fluctuations in symptom control. “Off” episodes occur when the benefit of levodopa diminishes before the next dose, leading to stiffness, slowed movement, and impaired mobility. Xadago is prescribed specifically to help reduce these periods and improve overall motor function.

For patients requiring long-term adjunctive therapy, accessing medication affordably is essential. Purchasing Xadago or Onstryv through regulated services such as LifePath Meds may offer cost savings while maintaining pharmaceutical quality standards.

What Is Xadago (Safinamide)?

Xadago is a prescription-only medicine classified as a selective MAO-B inhibitor. It is not intended as monotherapy for Parkinson’s disease. Instead, it must be used alongside levodopa/carbidopa in adults experiencing “off” episodes despite optimised levodopa treatment.

By selectively inhibiting the MAO-B enzyme, safinamide reduces the breakdown of dopamine in the brain. Dopamine is a neurotransmitter essential for coordinated movement. In Parkinson’s disease, dopamine-producing neurons progressively degenerate, leading to motor impairment. Supporting and prolonging dopamine activity is therefore a central therapeutic strategy.

Regulatory authorities such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have approved safinamide as adjunct therapy in Parkinson’s disease based on clinical trials demonstrating reduction in “off” time when added to levodopa.

How Xadago Works: Mechanism of Action

Safinamide works primarily through selective and reversible inhibition of monoamine oxidase B (MAO-B), an enzyme responsible for dopamine metabolism in the brain. By inhibiting MAO-B, safinamide slows dopamine breakdown, thereby prolonging its availability at synaptic sites.

This mechanism complements levodopa therapy. Levodopa increases dopamine production, while safinamide helps maintain dopamine levels for longer periods. The result is improved motor control and a reduction in daily “off” episodes.

Safinamide’s action is selective for MAO-B at recommended doses. However, exceeding prescribed dosages may reduce selectivity and increase the risk of adverse effects, including hypertension and serotonin syndrome.

Clinical Benefits of Xadago in Parkinson’s Disease

• Reduction in daily “off” time when added to levodopa/carbidopa
• Improved motor symptom control
• Prolonged “on” time without troublesome dyskinesia
• Once-daily oral dosing for convenience

Clinical trials evaluating safinamide as adjunct therapy have shown meaningful reductions in “off” time compared with placebo when added to stable levodopa regimens. Treatment goals in Parkinson’s disease focus on optimising motor function while minimising adverse effects and preserving quality of life.

Dosage and Administration Guidelines

The usual starting dose of Xadago is 50 mg once daily. After two weeks, depending on individual response and tolerability, the prescribing clinician may increase the dose to 100 mg once daily.

Administration Instructions

• Take at the same time each day.
• May be taken with or without food.
• Swallow tablets whole with water.

Do not exceed the prescribed dose. Higher doses may increase the risk of serious adverse effects, including elevated blood pressure and serotonin syndrome.

Xadago must be used in conjunction with levodopa/carbidopa. It is not approved as a standalone treatment for Parkinson’s disease.

Possible Side Effects

Common Side Effects

• Dyskinesia (involuntary movements)
• Nausea
• Insomnia
• Falls

Serious but Less Common Reactions

• Serotonin syndrome (symptoms may include fever, agitation, increased reflexes)
• Hallucinations and psychotic behaviour
• Impulse control disorders (e.g., gambling, hypersexuality, compulsive shopping)
• Hypertension

Contact a healthcare professional immediately if serious symptoms occur. Monitoring is especially important in patients with a history of psychiatric illness or cardiovascular disease.

Drug Interactions

Xadago may interact with several medicines. Patients must provide a complete list of prescriptions, over-the-counter medicines, and supplements to their healthcare provider.

Notable interaction risks include:

• Other MAO inhibitors
• Opioids such as tramadol or methadone
• Selective serotonin reuptake inhibitors (SSRIs)
• Serotonin-norepinephrine reuptake inhibitors (SNRIs)
• Dextromethorphan-containing products

Concomitant use with serotonergic medicines increases the risk of serotonin syndrome, a potentially life-threatening condition.

Precautions Before Starting Xadago

Inform your healthcare provider if you have:

• High or low blood pressure
• Cardiac disease
• History of psychosis or bipolar disorder
• Liver impairment

Liver function may influence dosing decisions. Additional monitoring may be required for patients with hepatic impairment.

Storage Instructions

• Store between 15°C and 30°C.
• Protect from moisture and excessive heat.
• Keep out of reach of children and pets.

Buying Xadago or Onstryv Online

Xadago is often required long term, which may result in substantial cumulative cost. Purchasing through licensed and reputable services such as LifePath Meds may offer savings compared with domestic pricing structures.

Steps for Safe Online Purchasing

• Verify pharmacy licensing and credentials.
• Consult your prescribing clinician before ordering.
• Understand import regulations (for example, the FDA generally permits a 90-day personal-use supply under certain circumstances).

Frequently Asked Questions (FAQs)

What is the difference between Xadago and Onstryv?

There is no pharmacological difference. Both brand names contain safinamide and provide identical therapeutic effects.

Can Xadago be used alone?

No. Xadago is approved only as adjunct therapy with levodopa/carbidopa.

How can I reduce the cost of Xadago?

Using licensed international pharmacy referral services such as LifePath Meds may reduce out-of-pocket expenses.